OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

There actually was an RNS Number:6130E but for some reason it wasnt picked up on all news services.

Thanks again - I am limited to picking up news from MoneyAM Stockwatch obviously on the stock I hold. How did you get hold of RNS 6130?

Normally I use
http://www.uk-wire.com/ but that wasnt picked up this morning on there. It was on ADVFN though http://www.advfn.com/p.php?pid=news&epic=OXB&cb=1099057225

:-)

Just as I said, an RNS would scupper my plan to buy some more at 16p.

i see one of the brokers, (can't remember which) has put a 45p target on these.

Panmure Gordon = Oxford Biomedica (OXB.L) (45p price target).

Isn't Panmure OXBs broker ???

Yes

Patrick Evershed's fund has a very large holding in this one and as he is AAA rated I followed him and bought a few. He said expect lots of positive news from OXB over the next few months---looks like it is starting to come through!!

UP again, will it break through 22p?

That could be interesting.

Looking at the 1 Year gragh I think a move upwards is on the cards. If it breaks the 22p mark then 25p is the next hurdle. Loads of products at phase 3 in their trials so im holding on for the long term.

Hearing rumours that GTAC has concerns re the safety of some lentiviruses that are used in Pro-Sarin. Anybody heard anything ?

Janus

Where did you hear / read these rumours from ????

A friend who is a doctor mentioned it, trying to find out more

More false rumours please, so that I can buy some more at a better price :-)

I have now seen a copy of a letter sent out by Professor Norman C Nevin GTAC Chairman, warning of concerns over the safety of some lentiviral gene therapy vectors. This states that reports have been received of the development of liver tumours in a pre-clinical study using lentiviral vectors. Most of the tumours occurred in a group of mice that had been treated in utero with a vector carrying the factor IX gene, although a small number of tumours were also observed in animals that had been treated neonatally or had received vectors carrying only marker genes.

The letter states that the number of mice involved is small and the wider implications are not yet clear. It also says that these observations do not appear to affect any current or previous UK trials so I have no idea how this affects OXB.

Not a problem, OXB have something for tumours aswell :)

lol well thats ok then :-)

Should be able to get a better price soon by the look of things.

has great potential...50p on the cards.